3-Aryl/Heteroary1-5-amino-1-(3′,4′,5′-trimethoxybenzoy1)-1,2,4-triazoles as antimicrotubule agents. Design, synthesis, antiproliferative activity and inhibition of tubulin polymerization

被引:17
作者
Romagnoli, Romeo [1 ]
Prencipe, Filippo [1 ]
Oliva, Paola [1 ]
Baraldi, Stefania [1 ]
Baraldi, Pier Giovanni [1 ]
Brancale, Andrea [2 ]
Ferla, Salvatore [2 ]
Hamel, Ernest [3 ]
Bortolozzi, Roberta [4 ]
Viola, Giampietro
机构
[1] Univ Ferrara, Dipartimento Sci Chim & Farmaceut, I-44121 Ferrara, Italy
[2] Cardiff Univ, Sch Pharm & Pharmaceut Sci, King Edward VII Ave, Cardiff CF10 3NB, S Glam, Wales
[3] NCI, Screening Technol Branch, Dev Therapeut Program,NIH, Div Canc Treatment & Diag,Frederick Natl Lab Canc, Frederick, MD 21702 USA
[4] Univ Padua, Lab Oncoematol, Dipartimento Salute Donna & Bambino, I-35131 Padua, Italy
关键词
Microtubule targeting-agent; Structure-activity relationship; Tubulin polymerization; Antiproliferative activity; Molecular docking; COLCHICINE BINDING-SITE; MICROTUBULE ORGANIZATION; ANTICANCER AGENTS; SOLID TUMORS; CANCER; GROWTH; 3(5)-AMINO-1,2,4-TRIAZOLES; COMBRETASTATIN-A-4; DERIVATIVES; ANALOGS;
D O I
10.1016/j.bioorg.2018.06.037
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Many natural and synthetic substances are known to interfere with the dynamic assembly of tubulin, preventing the formation of microtubules. In our search for potent and selective antitumor agents, a novel series of 1(3',4',5'-trimethoxybenzoyl)-5-amino-1,2,4-triazoles were synthesized. The compounds had different heterocycles, including thiophene, furan or the three isomeric pyridines, and they possessed a phenyl ring bearing electron-releasing or electron-withdrawing substituents at the 3-position of the 5-amino-1,2,4-triazole system. Most of the twenty-two tested compounds showed moderate to potent antiproliferative activities against a panel of solid tumor and leukemic cell lines, with four (5j, 5k, 5o and 5p) showing strong antiproliferative activity (IC50 < 1 mu M) against selected cancer cells. Among them, several molecules preferentially inhibited the proliferation of leukemic cell lines, showing IC50 values 2-100-fold lower for Jurkat and RS4;11 cells than those for the three lines derived from solid tumors (HeLa, HT-29 and MCF-7 cells). Compound 5k strongly inhibited tubulin assembly, with an IC50 value of 0.66 mu M, half that obtained in simultaneous experiments with CA-4 (IC50 = 1.3 mu M).
引用
收藏
页码:361 / 374
页数:14
相关论文
共 45 条
  • [21] Katsetos CD, 2012, CURR PHARM DESIGN, V18, P2778
  • [22] Recent developments in tubulin polymerization inhibitors: An overview
    Kaur, Ramandeep
    Kaur, Gurneet
    Gill, Rupinder Kaur
    Soni, Richard
    Bariwal, Jitender
    [J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2014, 87 : 89 - 124
  • [23] Current State of the Art of New Tubulin Inhibitors in the Clinicd
    Kuppens, Isa E. L. M.
    [J]. CURRENT CLINICAL PHARMACOLOGY, 2006, 1 (01): : 57 - 70
  • [24] ANTIMITOTIC NATURAL-PRODUCTS COMBRETASTATIN-A-4 AND COMBRETASTATIN-A-2 - STUDIES ON THE MECHANISM OF THEIR INHIBITION OF THE BINDING OF COLCHICINE TO TUBULIN
    LIN, CM
    HO, HH
    PETTIT, GR
    HAMEL, E
    [J]. BIOCHEMISTRY, 1989, 28 (17) : 6984 - 6991
  • [25] A phase I clinical trial assessing the safety and tolerability of combretastatin A4 phosphate injections
    Liu, Peng
    Qin, Yan
    Wu, Lingying
    Yang, Sheng
    Li, Nan
    Wang, Haijun
    Xu, Haiyan
    Sun, Kelin
    Zhang, Shuxiang
    Han, Xiaohong
    Sun, Yan
    Shi, Yuankai
    [J]. ANTI-CANCER DRUGS, 2014, 25 (04) : 462 - 471
  • [26] Tubulin inhibitors: a patent review
    Liu, Yi-Min
    Chen, Hsiao-Ling
    Lee, Hsueh-Yun
    Liou, Jing-Ping
    [J]. EXPERT OPINION ON THERAPEUTIC PATENTS, 2014, 24 (01) : 69 - 88
  • [27] An Overview of Tubulin Inhibitors That Interact with the Colchicine Binding Site
    Lu, Yan
    Chen, Jianjun
    Xiao, Min
    Li, Wei
    Miller, Duane D.
    [J]. PHARMACEUTICAL RESEARCH, 2012, 29 (11) : 2943 - 2971
  • [28] Synthesis and pharmacological activity of triazole derivatives inhibiting eosinophilia
    Naito, Y
    Akahoshi, F
    Takeda, S
    Okada, T
    Kajii, M
    Nishimura, H
    Sugiura, M
    Fukaya, C
    Kagitani, Y
    [J]. JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (15) : 3019 - 3029
  • [29] Phase I Trial of Combretastatin A4 Phosphate (CA4P) in Combination with Bevacizumab in Patients with Advanced Cancer
    Nathan, Paul
    Zweifel, Martin
    Padhani, Anwar R.
    Koh, Dow-Mu
    Ng, Matthew
    Collins, David J.
    Harris, Adrian
    Carden, Craig
    Smythe, Jon
    Fisher, Nita
    Taylor, N. Jane
    Stirling, J. James
    Lu, Shiao-Ping
    Leach, Martin O.
    Rustin, Gordon J. S.
    Judson, Ian
    [J]. CLINICAL CANCER RESEARCH, 2012, 18 (12) : 3428 - 3439
  • [30] Natural antitubulin agents: Importance of 3,4,5-trimethoxyphenyl fragment
    Negi, Arvind S.
    Gautam, Yashveer
    Alam, Sarfaraz
    Chanda, Debabrata
    Luqman, Suaib
    Sarkar, Jayanta
    Khan, Feroz
    Konwar, Rituraj
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (03) : 373 - 389